Stryker Corporation (SYK)
- Previous Close
381.36 - Open
379.13 - Bid 366.50 x 800
- Ask 390.00 x 1100
- Day's Range
373.98 - 381.57 - 52 Week Range
314.93 - 406.19 - Volume
1,823,404 - Avg. Volume
1,682,093 - Market Cap (intraday)
145.742B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
51.57 - EPS (TTM)
7.32 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield 3.36 (0.88%)
- Ex-Dividend Date Mar 31, 2025
- 1y Target Est
424.26
Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, cranial, and maxillofacial and chest wall devices, as well as dural substitutes and sealants; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries; thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
www.stryker.comRecent News: SYK
View More
Performance Overview: SYK
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYK
View MoreValuation Measures
Market Cap
144.27B
Enterprise Value
158.65B
Trailing P/E
51.02
Forward P/E
28.17
PEG Ratio (5yr expected)
0.49
Price/Sales (ttm)
6.28
Price/Book (mrq)
6.89
Enterprise Value/Revenue
6.83
Enterprise Value/EBITDA
28.20
Financial Highlights
Profitability and Income Statement
Profit Margin
12.31%
Return on Assets (ttm)
7.49%
Return on Equity (ttm)
14.26%
Revenue (ttm)
23.22B
Net Income Avi to Common (ttm)
2.86B
Diluted EPS (ttm)
7.32
Balance Sheet and Cash Flow
Total Cash (mrq)
2.41B
Total Debt/Equity (mrq)
82.92%
Levered Free Cash Flow (ttm)
3.03B
Research Analysis: SYK
View MoreResearch Reports: SYK
View MoreStryker Earnings: Another Stellar Quarter on the Books With Contained Tariff Impact
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
RatingPrice TargetThe Argus Innovation Model Portfolio
The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the recent period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as AI and vaccines) and services (such as Zoom calls and Netflix), as well as moving into new markets (clean energy, rare drugs), the domestic economy would not be growing, and capital would not be flooding into the country. Consider that U.S. GDP was approximately $1 trillion in 1930 but was almost $30 trillion at the end of 2024. That's growth of 30-times. Meanwhile, the U.S. population has grown less than 3-times during that time span, to 340 million from 120 million. The delta between GDP growth and population growth has been driven, in large part, by innovation.
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
RatingPrice TargetStryker Rides Wave as New Products See Continued Adoption
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
RatingPrice Target